

PTO-1449 REPRODUCED				ATTORNEY DOCKET NO. 2891.1001-026		APPLICATION NO. 09/754,004	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION January 30, 2001 (Use several sheets if necessary)				APPLICANT Marc Feldmann and Ravinder N. Maini			
				FILING DATE January 3, 2001		GROUP 1644	
PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AG	AA	5,656,272	12-AUG-97	Le et al.	424	133.1	—
	AB	5,741,488	21-APR-98	Feldmann et al.	424	154.1	—
	AC	5,698,195	16-DEC-97	Le et al.	424	133.1	—
	AD	5,919,452	06-JUL-99	Le et al.	424	133.1	—
	AE	5,317,019	31-MAY-94	Bender et al.	514	224.2	—
	AF	5,672,347	30-SEP-97	Aggarwal et al.	424	139.1	—
	AG	6,015,557	18-JAN-00	Tobinick et al.	424	134.1	—
	AH	6,177,077 B1	23-JAN-01	Tobinick	424	134.1	—
	AI	5,958,413	28-SEP-99	Anagnostopulos et al.	424	178.1	—
	AJ	5,795,967	18-AUG-98	Aggarwal et al.	530	388.23	—
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	WO 89/08460	21-SEP-89	PCT	—	—	—
	AM	WO 92/08474	29-MAY-92	PCT	—	—	—
	AN	WO 92/07585	14-MAY-92	PCT	—	—	—
	AO	WO 92/16553	01-OCT-92	PCT	—	—	—
	AP	WO 95/09652	13-APR-95	PCT	—	—	—
	AQ	WO 96/33204	24-OCT-96	PCT	—	—	—
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AR	Horneff, G., et al., "Elevated Levels of Circulating Tumor Necrosis Factor- $\alpha$ , Interferon- $\gamma$ , and Interleukin-2 in Systemic Reactions Induced by Anti-CD4 Therapy in Patients with Rheumatoid Arthritis," <i>Cytokine</i> , 3(3):266-247 (1991).					
	AS	Brennan, F., et al., "Inhibitory Effect of TNF $\alpha$ Antibodies on Synovial Cell Interleukin-1 Production in Rheumatoid Arthritis," <i>The Lancet</i> , 2(8657):244-247 (1989).					
RC	AT	Steinbruchel, D., et al., "Monoclonal Antibody Treatment (anti-CD4 and anti-interleukin-2 receptor) Combined with Cyclosporin A has a Positive but not Simple Dose-Dependent Effect on Rat Renal Allograft Survival," <i>Scandinavian J. Immunol.</i> , 34(5):627-633 (1991).					
EXAMINER PHILIP GAMZEL 12/5/01				DATE CONSIDERED			

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

January 30, 2001

(Use several sheets if necessary)

ATTORNEY DOCKET NO.  
2891.1001-026APPLICATION NO.  
09/754,004APPLICANT  
Marc Feldmann and Ravinder N. MainiFILING DATE  
January 3, 2001GROUP  
1644

## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
06	AL2 WO 98/24463	11-JUN-98	PCT			
	AM2 WO 00/50079	31-AUG-00	PCT			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AU	Breedveld, F., et al., "Anti-CD4 Antibodies in Rheumatoid Arthritis", <i>Clinical and Experimental Rheumatology</i> , 10(4):325-326 (1992).
AV	Brennan, F., et al., "TNF $\alpha$ -a Pivotal Role in Rheumatoid Arthritis?," <i>British J. Rheumatology</i> , 31(5):293-298 (1992).
AW	Elliott, M.J. et al., "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to TNF- $\alpha$ : Safety, Clinical Efficacy and Control of the Acute Phase Response," <i>Cell. Biochemistry, Supplement</i> , 0(17B):145 (1993); Abstract EZ405.
AX	Williams, R.O., et al., "Synergy Between Anti-CD4 and Anti-Tumor Necrosis Factor in the Amelioration of Established Collagen-Induced Arthritis," <i>Proc. Natl. Acad. Sci. USA</i> , 91:2762-2766 (1994).
AY	Ralph, P., "Clinical and Preclinical Studies Presented at the Keystone Symposium on Arthritis, Related Diseases, and Cytokines," <i>Lymphokine and Cytokine Research</i> , 12(4):261-263 (1993).
AZ	Racadot, E., "Immunological Follow-up of 17 Patients with Rheumatoid Arthritis Treated in vivo with an Anti-T CD4+ Monoclonal Antibody (B-F5)," <i>Clinical and Experimental Rheumatology</i> , 10:365-374 (1992).
AR2	Williams, R.O., et al., "Successful Therapy of Collagen-Induced Arthritis with TNF Receptor-IgG Fusion Protein and Combination with Anti-CD4," <i>Immunology</i> , 84:433-439 (March 1995).

EXAMINER

PHILIP GAMBEL 12/5/02

DATE CONSIDERED

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  January 30, 2001  (Use several sheets if necessary)		ATTORNEY DOCKET NO. 2891.1001-026	APPLICATION NO. 09/754,004				
		APPLICANT Marc Feldmann and Ravinder N. Maini					
		FILING DATE January 3, 2001	GROUP 1644				
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
pg	AS2	Van Der Lubbe, P.A., et al., "A Randomized, Double-Blind, Placebo-Controlled Study of CD4 Monoclonal Antibody Therapy in Early Rheumatoid Arthritis," <i>Arth. Rheum.</i> , 38(8):1097-1106 (1995).					
	AT2	Choy, E.H.S., et al., "Therapeutic Monoclonal Antibodies," <i>British J. Rheumatology</i> , 34:707-715 (1995).					
	AU2	Rankin, E.C.C., et al., "The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis," <i>British J. Rheumatology</i> , 34:334-342 (1995).					
	AV2	Butler, D.M., et al., "Modulation of Proinflammatory Cytokine Release in Rheumatoid Synovial Membrane Cell Cultures. Comparison of Monoclonal Anti TNF- $\alpha$ Antibody with the Interleukin-1 Receptor Antagonist," <i>Eur. Cytokine Netw.</i> , 6(4):225-230 (1995).					
	AW2	Horneff, G., et al., "Treatment of Rheumatoid Arthritis with an Anti-CD4 Monoclonal Antibody," <i>Arthritis &amp; Rheumatism</i> , 34(2):129-140 (1991).					
	AX2	Van Dullemen, H.M., et al., "Treatment of Crohn's Disease with Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)," <i>Gastroenterology</i> , 109(1):129-135 (1995).					
	AY2	Watts, R.A., and Isaacs, J.D., "Immunotherapy of Rheumatoid Arthritis," <i>Annals Rheumatic Diseases</i> , 51:577-579 (1992).					
p	AZ2	Schacht, E., "Gegenwärtige und Zukünftige Therapiestrategien der Rheumatoiden Arthritis (RA)," ["The Current and Future Therapy Strategies of Rheumatoid Arthritis (RA)"], <i>Zeitschrift für Rheumatologie</i> , 52(6):365-382 (1993).					
EXAMINER				DATE CONSIDERED			
Phuup Gamox 11/5/01							

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2891.1001-026	APPLICATION NO. 09/754,004
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		APPLICANT Marc Feldmann and Ravinder N. Maini	
January 30, 2001 (Use several sheets if necessary)		FILING DATE January 3, 2001	GROUP 1644
OTHER DOCUMENTS (Include Author, Title, Date, Pertinent Pages, Etc.)			
AR3	Elliott, M.J., et al., "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to TNF $\alpha$ ", <i>Rev. Esp. Reumatol</i> , 20 Suppl. 1:148 (1993); Abstract 320.		
AS3	Elliott, M.J., et al., "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to Tumor Necrosis Factor $\alpha$ ," <i>Arth. Rheum.</i> , 36(12):1681-1690 (1993).		
AT3	Elliott, M.J., et al., "Randomised Double-Blind Comparison of Chimeric Monoclonal Antibody to Tumor Necrosis Factor $\alpha$ (cA2) Versus Placebo in Rheumatoid Arthritis," <i>The Lancet</i> 344:1105-1110 (1994).		
AU3	Elliott, M.J., et al., "Repeated Therapy with Monoclonal Antibody to Tumor Necrosis Factor $\alpha$ (cA2) in Patients with Rheumatoid Arthritis," <i>The Lancet</i> 344:1125-1127 (1994).		
AV3	Maini, R.N., et al., "Clinical Response of Rheumatoid Arthritis (RA) to Anti-TNF $\alpha$ (cA2) Monoclonal Antibody (mab) is Related to Administered Dose and Persistence of Circulating Antibody," <i>Arth. Rheum. Supplement</i> , 38(9):S186 (1995); Abstract 200.		
AW3	Maini, R.N., "The Role of Cytokines in Rheumatoid Arthritis," <i>J. Royal College of Physicians of London</i> , 30(4):344-351 (1996).		
AX3	Kalden, J.R., and Manger, B., "Biologic Agents in the Treatment of Inflammatory Rheumatic Diseases," <i>Curr. Opin. Rheum.</i> , 7 :191-297 (1995).		
AY3	Bologna, C., and Sany, J., "Association des Traitements de Fond dans la Polyarthrite Rhumatoide," <i>Presse Med.</i> , 25:876-878 (1996).		
AZ3	Borigini, M.J., and Paulus, H.E., "Combination Therapy," <i>Baillière's Clin. Rheum.</i> , 9(4):689-710 (1995).		
AR4	Kalden, J.R., and Manger, B., "Biologic Agents in the Treatment of Inflammatory Rheumatic Diseases," <i>Curr. Opin. Rheum.</i> , 9:206-212 (1997).		
AS4	Kavanaugh, A., et al., "Anti-TNF- $\alpha$ Monoclonal Antibody (mAb) Treatment of Rheumatoid Arthritis (RA) Patients With Active Disease On Methotrexate (MTX); Results of a Double-Blind, Placebo Controlled Multicenter Trial," <i>Arth. Rheum.</i> , 39(Suppl.9): 18-22 (October 1996), Abstract 575.		
AT4	Debets, R., et al., "Cytokine Antagonists and their Potential Therapeutic Use," <i>Immunology Today</i> , 15:455-458 (1994).		
AU4	Manual of Medical Therapeutics, 25 <sup>th</sup> Edition, Orian et al, (editors), Dept. of Medicine, Washington University, St. Louis, MO, Pages 308-309 (1986).		
AV4	Paul, W.E., ed., "Tumor Necrosis Factor," In <i>Fundamental Immunology</i> , 3 <sup>rd</sup> edition (NY:Raven Press), pages 807-812 (1993).		
EXAMINER  Philip Gambel 12/5/01		DATE CONSIDERED	

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2891.1001-026	APPLICATION NO. 09/754,004
INFORMATION DISCLOSURE CITATION IN AN APPLICATION  January 30, 2001 (Use several sheets if necessary)		APPLICANT Marc Feldmann and Ravinder N. Maini	
		FILING DATE January 3, 2001	GROUP 1644
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
AW4	Natanson, C. et al., "Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis," <i>Ann. Int. Med.</i> , 120(9):771-783 (1994).		
AX4	Paul, W.E., ed., <i>Fundamental Immunology</i> , 3 <sup>rd</sup> edition (NY:Raven Press), page 242 (1993).		
AY4	Hervé, P., et al., "Phase I-II Trial of a Monoclonal Anti-Tumor Necrosis Factor $\alpha$ Antibody for the Treatment of Refractory Severe Acute Graft-Versus-Host Disease," <i>Blood</i> , 79:3362-3368 (1992).		
AZ4	Barrera, P., et al., "Effects of a Weekly Dosis of Methotrexate on IL-1 TNF and IL-6 in Patients with Rheumatoid Arthritis," <i>Cytokine</i> , 3(5):504, Abstract 330 (1991).		
AR5	Kozarek, R.A., et al., "Methotrexate Induces Clinical and Histologic Remission in Patients with Refractory Inflammatory Bowel Disease," <i>Ann. Int. Med.</i> , 110:353-356 (1989).		
AS5	Markowitz, J., et al., "Immunology of Inflammatory Bowel Disease: Summary of the Proceedings of the Subcommittee on Immunosuppressive Use in IBD," <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 12(4):411-423 (1991).		
AT5	Cohen, S., et al., "Comparison of the Safety and Efficacy of Cyclosporine-A and Methotrexate in Refractory Rheumatoid Arthritis: A Randomized, Multi-Centered Placebo-Controlled Trial," <i>Rev. Esp. Rheumatol.</i> , 20 Suppl. 1:148 (1993), Abstract 318.		
AU5	Pascalis, L., et al., "Longterm Efficacy and Toxicity of Combined Cyclosporine A-Steroid-Methotrexate Treatment in Rheumatoid Arthritis," <i>Rev. Esp. Rheumatol.</i> , 20 Suppl. 1:148 (1993), Abstract 319.		
AV5	Brahn, E. et al., "Effects of Tumor Necrosis Factor and Combination Cyclosporine A/Methotrexate Therapy on Collagen Arthritis," <i>Arthritis &amp; Rheumatism</i> , 32(Suppl. 4):S133 (1992), Abstract D42.		
EXAMINER		DATE CONSIDERED	
PHILLIP GAMBER 14562			